Comment by mchusma
16 hours ago
I actually think a reasonable strategy of Google is to focus on biotech, where the demand for compute is infinite, and focus on cost effective solutions with really good search for other verticals (eg legal, accounting, etc), and offer loss leaders in coding to undercut Anthropic/openai, with “cheap just behind the frontier” models.
They are not really doing this, but it makes sense to me.
Yeah, I would be curious to know what kind of returns they’re seeing from Isomorphic labs given AlphaFold itself is publicly available. From what I’ve read, the deals they’ve reached with the major Pharma companies could result in billions in returns, but they come as royalties or are tied to performance metrics. It’s going to be hard to know how valuable the investments made in this space will be for probably another decade.